A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2624 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Volunteers of Non-child-bearing Potential
Study identifier:D0970C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2624 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Volunteers of Non-child-bearing Potential
Medical condition
schizophrenia
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
